Alkaline phosphatase (ALP): Liver, bones, and the hidden link to longevity

Quick answer

If ALP is already flagged high, use the alkaline phosphatase high workflow to sort liver, bone, and lab-noise sources.

Alkaline phosphatase (ALP) is a blood enzyme that mainly reflects liver bile-duct activity, bone turnover, and, in some contexts, intestinal biology. Higher ALP within or above the lab range is associated with higher mortality and vascular-calcification risk in population studies, but interpretation depends on GGT, bilirubin, calcium, phosphate, vitamin D, age, pregnancy status, and bone health.

Key facts

• ALP -> liver bile ducts and bone osteoblasts -> two common sources of elevation.
• High ALP + high GGT -> liver or bile-flow pattern is more likely.
• High ALP + normal GGT -> bone turnover, vitamin D deficiency, or other non-liver sources become more likely.
• Persistently low ALP -> consider zinc/magnesium status, hypothyroidism, or rare hypophosphatasia.
• Higher-normal ALP -> associated with mortality and vascular risk in cohorts; treat it as a follow-up signal, not a diagnosis or a treatment target by itself.

Open your latest blood test report and look for the entry “alkaline phosphatase” (or ALP). Your doctor probably never commented on it — unless it was dramatically out of range.

Yet this enzyme, which most people ignore, is one of the 9 biomarkers used by the PhenoAge formula to estimate biological age. And research from recent years has revealed something important: higher-normal ALP levels are associated with a higher risk of mortality in large cohorts, even when values remain inside many lab reference ranges.

An NHANES study of over 34,000 adults followed for nearly 12 years showed that those with ALP in the highest quartile had an all-cause mortality risk 30% higher than the lowest quartile after full adjustment. Unadjusted cardiovascular death rates were more than twice as high in the highest quartile, but the fully adjusted association was smaller, which is why context matters.

The good news? ALP is often a modifiable parameter once the source is understood. In this article, you’ll discover what alkaline phosphatase really is, why higher values track aging risk, and what you can concretely do with your clinician to interpret it.

For a lab-report reference page with ranges, aliases, and SuperAge context, see the alkaline phosphatase biomarker guide.

What you’ll learn:

• What alkaline phosphatase is and how it works
• The 3 types of ALP: liver, bone, and intestine
• Normal values vs. practical tracking zones
• ALP and aging: what science says
• The centenarian study: the biochemical profile of those who live 100 years
• High ALP: causes, risks, and mechanisms
• Low ALP: when to worry
• 6 evidence-based strategies to optimize ALP
• How SuperAge tracks ALP and calculates your biological age
• FAQ

---

What Is Alkaline Phosphatase?

Alkaline phosphatase is an enzyme — a protein that accelerates chemical reactions in the body. Its main function is to remove phosphate groups from molecules like proteins, nucleotides, and alkaloids, a process called dephosphorylation.

Quick definition: Alkaline phosphatase (ALP) is an enzyme present in liver, bones, intestine, and kidneys, whose blood level reflects hepatic health, bone metabolism, and inflammatory status. It’s one of the 9 biomarkers used to calculate biological age with the PhenoAge formula.

The name “alkaline” comes from the fact that it works best in an alkaline pH environment (pH 9-10), much higher than normal blood pH (7.4). This technical detail is important: ALP is particularly active in tissues where the local pH tends to be higher.

Why ALP Is Unique Among Biomarkers

Unlike albumin (which is a single protein produced by the liver) or blood glucose (which measures a single metabolite), ALP in the blood is actually a mix of different enzymes from different organs. This makes it complex to interpret — but also incredibly informative.

Elevated ALP could mean a problem with the liver, bones, intestine, or a combination of these. And as we’ll see, values in the higher part of common adult ranges are associated with higher aging-related risk in cohorts, but they still need GGT, bilirubin, calcium, phosphate, vitamin D, kidney function, and clinical context before anyone should act on them.

---

The 3 Types of ALP: Liver, Bone, and Intestine

The ALP circulating in the blood is not a single enzyme, but a mixture of isoenzymes from different tissues. Understanding which type is responsible for an elevated value is fundamental to correctly interpreting the tests.

Hepatic ALP (~40% of total)

The hepatic isoenzyme is produced by the cells of the liver’s bile ducts. It rises when there’s an obstruction to bile flow (cholestasis) or damage to the bile ducts.

When it rises:

• Bile duct obstruction (gallstones, tumors)
• Hepatitis and cirrhosis
• Fatty liver (NAFLD/NASH)
• Hepatotoxic drugs
• Hepatic infiltration (metastases, amyloidosis)

How to distinguish it: If ALP elevation is hepatic, gamma-GT (GGT) is often elevated too. If GGT is normal, a non-liver source becomes more likely.

Bone ALP (~40% of total)

The bone isoenzyme is produced by osteoblasts — the cells that build new bone tissue. It rises when bone turnover is accelerated.

When it rises:

• Fractures in the healing phase
• Paget’s disease (pathological bone turnover)
• Osteomalacia and rickets (vitamin D deficiency)
• Bone metastases
• Hyperparathyroidism
• Growth during childhood and adolescence (physiological)
• Menopause (increased bone resorption)

How to distinguish it: If bone ALP is the source, GGT is usually normal. The doctor can also request bone-specific alkaline phosphatase (BAP) or ALP fractionation to confirm.

Intestinal ALP (~20% of total)

The intestinal isoenzyme is the most fascinating from a longevity perspective. It’s produced by intestinal mucosa cells and has a unique protective role.

Key functions of intestinal ALP:

• Detoxifies lipopolysaccharide (LPS) — the bacterial toxin that causes systemic inflammation
• Maintains the intestinal barrier — prevents “leaky gut”
• Modulates the microbiota — promotes healthy bacterial balance
• Supports metabolic health in experimental models — eBioMedicine work suggests intestinal ALP can protect against diet-induced metabolic syndrome in mice, but this is not the same as using serum ALP as a diabetes test

ALP paradox: High serum ALP (in the blood) is often a negative risk signal. Intestinal ALP activity in the gut barrier may be protective. Same enzyme family, very different context.

Placental ALP

There’s also a fourth isoenzyme, produced by the placenta during pregnancy. It’s why total ALP can reach double the upper limit in the third trimester — a completely physiological variation.

---

Normal Values vs. Practical Tracking Zones

As with the other biomarkers in the series, the distinction between “clinically normal” and “worth following over time” is more useful than chasing a universal longevity target. ALP reference intervals vary by lab, age, sex, pregnancy status, assay method, and clinical setting.

Situation	Approximate value (U/L)	Interpretation
Persistently low	Often < 30-40	Repeat the test; consider lab artifact, malnutrition, zinc/magnesium deficiency, hypothyroidism, severe anemia, or rare hypophosphatasia
Lower-to-mid adult range	Roughly 40-80	Usually reassuring if stable and the rest of the liver-bone panel is clean
Higher adult range	Roughly 80-120	Often still normal by the lab, but worth interpreting with GGT, vitamin D, calcium, phosphate, CRP, and trend
High-normal or elevated	Roughly > 120 or above the lab range	Follow up for liver, bile-duct, bone, pregnancy, medication, kidney, or inflammatory sources
Very high	> 4x the upper reference limit	Prompt medical evaluation, especially for cholestasis or serious bone/liver disease

The difference between ALP at 70 U/L and 130 U/L can be meaningful, but it is not a standalone verdict. In the 2023 NHANES analysis, the highest ALP quartile was above 82 U/L, and risk rose after adjustment for many confounders. That does not mean everyone should drive ALP as low as possible: values that are too low can also signal a problem.

How ALP Changes with Age and Sex

ALP is not a static value. It varies significantly with age, sex, and hormonal status.

Life stage	What changes	How to interpret
Children/adolescents	ALP can be much higher because bones are growing	Use pediatric age-specific ranges, not adult longevity ranges
Healthy adults	Liver and bone isoenzymes dominate the blood value	Compare with the lab range, GGT, bilirubin, calcium, phosphate, vitamin D, and trend
After menopause	Bone turnover can raise ALP in some women	Interpret with bone health, vitamin D, calcium/phosphate, and fracture risk
Pregnancy	Placental ALP can rise, especially in the third trimester	Usually physiologic, but interpret with obstetric context
Chronic kidney disease or dialysis	Bone-mineral disorder changes the meaning of ALP	Needs clinician-led interpretation with PTH, phosphate, calcium, and dialysis context

Key point: In children and adolescents, ALP is physiologically very high (even 500 U/L) due to rapid bone growth. This is not a cause for concern.

ALP and the Other PhenoAge Biomarkers

Alkaline phosphatase is the eighth of the 9 biomarkers in the PhenoAge formula. In that model, it enters with a positive coefficient — higher ALP pushes the calculated age upward when the rest of the formula is held constant. This is a model property, not a reason to chase very low ALP.

The 9 PhenoAge biomarkers are:

1. Albumin ← read the article
2. Creatinine ← read the article
3. Glucose ← read the article
4. C-reactive protein (CRP)
5. Lymphocyte percentage ← read the article
6. Mean corpuscular volume (MCV) ← read the article
7. Red cell distribution width (RDW) ← read the article
8. Alkaline phosphatase (ALP) ← you are here
9. White blood cell count (WBC)

Deep dive: If you want to understand how PhenoAge and KDM work in detail, read our dedicated article: PhenoAge and KDM: how to calculate biological age from blood tests.

---

ALP and Aging: What Science Says

The link between alkaline phosphatase and aging is consistent across several observational settings, but it is best read as a risk marker that often reflects liver-bile, bone, kidney-mineral, inflammation, or metabolic context.

The NHANES Study: 34,000 People, 12 Years of Follow-up

The largest study on the subject was published in Frontiers in Endocrinology in 2023. Researchers analyzed data from 34,147 adults from the National Health and Nutrition Examination Survey (1999-2014), with a median follow-up of 139.7 months.

The results were consistent:

ALP Quartile	Approximate range	Fully adjusted all-cause mortality risk	Fully adjusted cardiovascular mortality risk
Q1	<=55 U/L	Reference	Reference
Q2	>55-67 U/L	Not significantly different	Not significantly different
Q3	>67-82 U/L	+23%	+33%
Q4	>82 U/L	+30%	+39%

In practice: raw cardiovascular death rates were more than twice as high in the highest quartile, but after adjustment for age, metabolic factors, kidney function, vitamin D, albumin, GGT, and other variables, the excess risk was about 39%. That is still meaningful, but it is not the same as ALP alone “doubling” risk (Li et al., 2023).

A 2025 Kidney360 analysis of 241,670 dialysis patients from a nationwide Japanese registry found higher ALP independently associated with all-cause mortality, cardiovascular mortality, and new hip fracture. The shape was not perfectly simple: in lower-PTH patients, all-cause mortality rose more linearly with ALP, while in higher-PTH patients very low ALP could also look unfavorable. That makes ALP a clinically meaningful context marker, not a standalone diagnosis (Maruyama et al., 2025).

The Mechanism: Vascular Calcification

One plausible link between ALP and cardiovascular risk is vascular calcification.

Tissue-nonspecific ALP can hydrolyze inorganic pyrophosphate — a molecule that normally helps prevent calcium deposits from forming on blood vessel walls. When this pathway is overactive in susceptible settings:

1. Protective pyrophosphate is degraded
2. Hydroxyapatite (calcium) crystals begin depositing on arteries
3. Arteries become rigid and less elastic (arteriosclerosis)
4. Risk of heart attack, stroke, and heart failure increases

This resembles the mineralization biology needed in bones, but in the vessel wall it contributes to soft-tissue calcification. The same pathway helps explain why ALP can track vascular calcification, especially in chronic kidney disease and other mineral-metabolism disorders (Sheen et al., 2015).

A 2025 study in Renal Failure of chronic hemodialysis patients reported a synergistic effect: when moderate-to-severe aortic arch calcification coexists with high serum ALP, the risk of major adverse cardiovascular events and all-cause mortality is amplified beyond either factor alone. In other words, high ALP may help identify calcification patterns with worse clinical consequences (Lee et al., 2025).

Emerging therapy: Pharmacological inhibition of tissue-nonspecific alkaline phosphatase (TNAP) is being studied for vascular calcification. A 2025 review describes animal and early human programs that try to raise pyrophosphate or reduce its breakdown, but hard clinical endpoints are still limited and long-term TNAP inhibition may affect bone. This remains investigational, not a routine clinical treatment (O’Brien et al., 2025).

ALP and Cognitive Decline

A study of 209 elderly individuals found that significantly higher ALP levels were present in people with subjective cognitive decline (Boccardi et al., 2021):

Cognitive Status	Mean ALP (U/L)
Healthy controls	139.9
Mild cognitive impairment (MCI)	164.5
Subjective cognitive decline	189.8

The difference between 140 and 190 U/L is notable, but this was a small observational signal. A larger 2024 NHANES analysis in older adults also found a non-linear association between liver enzymes and cognitive performance, including ALP, so the safer interpretation is that ALP may travel with vascular, inflammatory, or metabolic context relevant to cognition — not that it diagnoses brain aging by itself (Yang et al., 2024).

Intestinal ALP and Inflammaging

While high serum ALP is often a negative risk signal, there’s a fascinating flip side: intestinal alkaline phosphatase (IAP) may be protective inside the gut.

JCI Insight work has shown that:

• IAP decreases with age, contributing to intestinal barrier deterioration
• IAP supplementation in animal models reduces intestinal permeability and systemic inflammation
• IAP detoxifies bacterial endotoxins (LPS), reducing inflammaging — the chronic low-grade inflammation that accelerates aging

In practice: your gut has its own barrier-defense enzymes, and intestinal ALP is one candidate mechanism. This does not mean a routine blood ALP result measures your gut-barrier health (Kühn et al., 2020).

---

The Centenarian Study: The Biochemical Profile of Those Who Live 100 Years

The Swedish AMORIS Study: 35 Years of Data

The AMORIS (Apolipoprotein MOrtality RISk) study, published in GeroScience in 2023, followed 1,224 people who reached 100 within a cohort of 44,636 Swedish adults for up to 35 years.

Among the main findings: lower ALP, along with lower GGT, glucose, creatinine, uric acid, AST, LDH, and TIBC, was associated with a higher chance of reaching 100. The study does not turn ALP into a centenarian predictor by itself; it shows that future centenarians tended to have a more favorable multi-marker profile.

What did future centenarians have in common? An overall more favorable biochemical profile:

• Lower ALP
• Higher albumin
• Lower uric acid
• Slightly higher total cholesterol (paradoxically)
• Lower gamma-GT

The conclusion is clear: it’s not enough to have a single biomarker in the normal range. It’s the overall profile that counts. And ALP is one piece of this puzzle (Murata et al., 2023).

The Link with Cardiovascular Mortality in Large Studies

A publication in Arteriosclerosis, Thrombosis, and Vascular Biology analyzed ALP, phosphate, and cardiovascular outcomes in older men and found higher ALP associated with coronary heart disease, stroke events, cardiovascular mortality, and total mortality. It supports ALP as a vascular-risk marker, but not as a simple “per 10 U/L” rule for every adult (Wannamethee et al., 2013).

This means that ALP is more than a generic lab abnormality: it may reflect pathways involved in vascular damage, but the number still needs clinical context.

---

High ALP: Causes, Risks, and Mechanisms

Main Causes of Elevated ALP

Hepatic causes:

• Cholestasis (biliary obstruction from gallstones or tumors)
• Hepatitis (viral, alcoholic, autoimmune)
• Liver cirrhosis
• Non-alcoholic fatty liver disease (NAFLD/NASH)
• Hepatotoxic drugs
• Liver tumors or metastases

Bone causes:

• Paget’s disease
• Osteomalacia and rickets
• Hyperparathyroidism
• Healing fractures
• Bone metastases
• Postmenopausal osteoporosis

Physiological causes (non-pathological):

• Growth during childhood and adolescence (very high ALP, completely normal)
• Pregnancy (especially third trimester)
• Fat-rich meal (transient intestinal ALP, especially in blood groups O and B)

Other causes:

• Heart failure
• Chronic kidney failure
• Hyperthyroidism
• Infections (mononucleosis, CMV)
• Medications: anticonvulsants, antibiotics, oral contraceptives

How to Determine if ALP Comes from Liver or Bone

The most frequent diagnostic question is: is my high ALP hepatic or bone-related?

Additional Test	Hepatic ALP	Bone ALP
GGT (gamma-GT)	↑ Elevated	Normal
Transaminases (ALT/AST)	Often ↑	Normal
Serum calcium	Normal	May be ↑ (hyperparathyroidism)
Serum phosphate	Variable	May be ↓ (osteomalacia)
Vitamin D	Normal	Often ↓
BAP (bone-specific ALP)	Normal	↑ Elevated

Rule of thumb: If GGT is high along with ALP → a hepatic or bile-flow source is more likely. If GGT is normal and ALP is high → think about bones and other non-liver sources.

---

Low ALP: When to Worry

ALP that’s too low is less common than high ALP, but persistent low values should not be ignored. Many labs use a lower adult reference limit around 30-40 U/L, so the exact threshold depends on the report.

Main Causes of Low ALP

Nutritional deficiencies:

• Zinc deficiency — zinc is an essential ALP cofactor. Without zinc, the enzyme doesn’t function
• Magnesium deficiency — another necessary cofactor
• Vitamin C deficiency — rare, but possible
• Protein-calorie malnutrition — especially in the elderly

Medical conditions:

• Hypophosphatasia — a rare genetic disease involving the ALPL gene that causes persistently low ALP. It can lead to fractures, dental problems, chronic musculoskeletal pain, and abnormal mineralization
• Hypothyroidism — underactive thyroid reduces ALP
• Severe anemia — can lower ALP
• Post-cardiac surgery — transient decrease

When to Worry

ALP (U/L)	Situation	Action
30-40 or just below your lab range	Borderline or mildly low	Repeat if unexpected; review diet, thyroid, anemia, supplements, and medications
Persistently < 30-40	Low	Discuss zinc, magnesium, B12, thyroid, anemia, copper/ceruloplasmin, and other secondary causes
Very low plus bone pain, recurrent fractures, dental history, or family history	Possible hypophosphatasia signal	Ask your clinician whether hypophosphatasia workup is appropriate

Key point: If your ALP is chronically low, do not just supplement blindly. Confirm the result, exclude sample issues, and interpret it with symptoms and secondary causes.

---

6 Evidence-Based Strategies to Optimize ALP

The goal is not simply to “lower ALP” at any cost. The practical goal is to understand the source, keep the trend stable, and improve the liver, bone, kidney-mineral, metabolic, and inflammatory context around the number.

1. Protect the Liver (the Main Lever)

Why it works: The liver and bile ducts are major sources of serum ALP. Fatty liver disease, alcohol, cholestasis, medications, and bile-duct problems can all contribute to elevated ALP, especially when GGT is also high.

How to do it:

• Limit alcohol — especially if GGT, ALT, AST, triglycerides, or liver fat are also elevated
• Maintain a healthy body weight — losing 5-10% of body weight significantly reduces hepatic steatosis (e.g., for a 176 lb (80 kg) person, lose 9-18 lbs (4-8 kg))
• Reduce added sugars — excess fructose is particularly toxic to the liver
• Drink coffee if tolerated — coffee intake is associated with lower liver-disease risk in many cohorts
• Regularly check GGT and transaminases along with ALP

2. Optimize Vitamin D and K2

Why it works: Vitamin D deficiency is one of the most common causes of elevated bone-origin ALP. When vitamin D is low, bone metabolism becomes inefficient and bone ALP increases to compensate.

How to do it:

• Vitamin D: correct deficiency with your clinician; many adults use 25-hydroxyvitamin D testing rather than guessing
• Vitamin K2 (MK-7): may support calcium-handling biology, but it is not a proven treatment for high ALP or vascular calcification
• Moderate sun exposure — 15-20 minutes daily with arms and legs uncovered (when possible)

Advanced tip: Vitamin D, calcium, phosphate, PTH, and kidney function belong together. Avoid high-dose supplementation when you do not know the source of the ALP elevation.

3. Exercise Regularly

Why it works: Regular physical activity improves insulin sensitivity, reduces liver fat, modulates bone metabolism, and lowers inflammation — all factors that contribute to normalizing ALP.

How to do it:

• Aerobic exercise — 150 minutes weekly at moderate intensity (brisk walking at 3.1-3.7 mph (5-6 km/h))
• Resistance training — 2-3 sessions weekly to stimulate healthy (not pathological) bone turnover
• Avoid prolonged sedentariness — even standing up 5 minutes every hour makes a difference

Important note: Intense exercise can transiently elevate bone ALP (for hours or days). This is a signal of healthy bone remodeling, not a problem. Get blood tests done at rest (not the day after a marathon).

4. Control Weight and Metabolic Syndrome

Why it works: Metabolic syndrome (insulin resistance, hypertension, altered cholesterol, abdominal fat) is strongly associated with elevated ALP levels. A study in Journal of Clinical Endocrinology & Metabolism confirmed that hypertension, low HDL, and insulin resistance have direct effects on increasing ALP (Webber et al., 2013).

How to do it:

• Monitor waist circumference — target < 37 in (94 cm) for men, < 31.5 in (80 cm) for women
• Check fasting glucose and glycated hemoglobin (HbA1c)
• If overweight, even modest weight loss improves metabolic profile and lowers ALP

5. Support Intestinal ALP (the Positive Side)

Why it works: You are not trying to raise the ALP number in your blood. The idea is to support gut-barrier health, where intestinal ALP may help detoxify bacterial endotoxins and maintain microbial balance.

How to do it:

• Prebiotic fiber — inulin, FOS, fibers from fruits and vegetables nourish bacteria that stimulate IAP production
• Short-chain fatty acids (SCFAs) — produced by the microbiota when fermenting fibers. Butyrate in particular stimulates IAP production
• Avoid unnecessary antibiotics — they alter the microbiota and reduce IAP production
• Fermented foods — yogurt, kefir, sauerkraut, kimchi support microbiota diversity

6. Correct Zinc and Magnesium Deficiencies

Why it works: If your ALP is low, zinc or magnesium deficiency is one possibility because both are involved in ALP biology. But persistent low ALP also needs a broader differential.

How to do it:

• Zinc: food sources include oysters, red meat, pumpkin seeds, and legumes
• Magnesium: sources include leafy greens, nuts, seeds, and dark chocolate
• Check serum levels — both zinc and magnesium can be measured with a blood test

Advanced tip: Long-term zinc supplementation can lower copper status. If you supplement, dose and duration should match a documented need.

---

How SuperAge Tracks ALP and Calculates Your Biological Age

Monitoring alkaline phosphatase in the context of other aging biomarkers is where the real value emerges. An isolated ALP value says little — but inserted into the PhenoAge formula along with the other 8 parameters, it becomes a powerful indicator of your aging rate.

Automatic Extraction from Blood Tests

SuperAge uses Apple’s artificial intelligence to automatically extract ALP and other biomarkers from your reports:

• Automatic recognition of alkaline phosphatase (ALP, AP, Alk Phos — whatever abbreviation your lab uses)
• Unit conversion — U/L, IU/L, µkat/L: the app handles all variants
• Contextualization — doesn’t just tell you if you’re “in the normal range,” but helps place the result beside trend, GGT, liver enzymes, bone-mineral markers, and the rest of the aging panel

Integrated PhenoAge Calculation

ALP enters the PhenoAge formula with a positive coefficient. Translated into practice:

• ALP at 70 U/L → lower contribution to the PhenoAge risk score than ALP at 130 U/L, all else equal
• ALP at 130 U/L → pushes the calculated age upward, but the reason for the elevation matters more than the score alone
• Very low ALP → may also be clinically relevant, even if it looks “good” in a one-direction aging model

SuperAge calculates your complete PhenoAge and shows you the specific impact of each biomarker — so you know exactly which parameter to work on to lower your biological age.

Tracking Over Time

The real value is in the trend. ALP can vary for many reasons — a single value isn’t enough to draw conclusions. SuperAge saves every set of tests and lets you:

• See how ALP moves over time
• Correlate changes with specific interventions (e.g., vitamin D supplementation, weight loss)
• Receive alerts if the trend becomes concerning

Want to discover your biological age? Download SuperAge and upload your blood tests to calculate your PhenoAge in seconds.

---

Frequently Asked Questions

What is alkaline phosphatase (ALP) in blood tests?

Alkaline phosphatase is an enzyme present in liver, bones, intestine, and kidneys. In blood tests, its level reflects hepatic health, bone metabolism, and inflammatory status. It’s one of the 9 biomarkers used by the PhenoAge formula to estimate biological age.

What are normal alkaline phosphatase values?

The standard range is often around 44-147 U/L, but it varies by laboratory, age, sex, pregnancy status, and method. For tracking, lower-to-mid adult values are usually more reassuring than high-normal values, but there is no universal longevity target. Persistently low values can also need follow-up.

When should I worry about high alkaline phosphatase?

Values above your lab’s upper reference limit deserve medical interpretation with GGT, bilirubin, ALT/AST, vitamin D, calcium, phosphate, and clinical context. Chronically high-normal values can also be worth tracking, especially if they are rising or paired with high GGT, liver symptoms, bone pain, kidney disease, or inflammation.

How can I lower alkaline phosphatase naturally?

The main strategies are: identify the source, protect the liver, correct vitamin D or bone-mineral problems when present, exercise regularly, control metabolic syndrome, and support gut health. The cause determines the approach: if it is hepatic, work on the liver-bile pattern; if bone-related, check vitamin D, calcium, phosphate, PTH, and bone health.

Can high alkaline phosphatase accelerate aging?

It can be a signal worth following. Elevated ALP is linked to vascular calcification — the process by which calcium deposits on artery walls, making them rigid — and higher ALP enters the PhenoAge formula with a positive coefficient. Treat it as a risk marker to interpret with the rest of your blood panel, not as proof that aging is accelerating.

What’s the difference between hepatic ALP and bone ALP?

ALP in the blood is a mix of isoenzymes from liver, bones, intestine, and, during pregnancy, placenta. To distinguish them: if GGT is high along with ALP, a hepatic or bile-flow source is more likely. If GGT is normal, non-liver sources such as bone become more likely. A clinician can request ALP fractionation or bone-specific alkaline phosphatase (BAP) when needed.

Is low ALP a problem?

Yes, if persistent and below your age- and sex-adjusted reference range. Causes include nutritional deficiencies, hypothyroidism, severe anemia, certain medications, and rare hypophosphatasia. If low ALP is repeated and accompanied by fractures, bone pain, dental history, or family history, it deserves a more specific workup.

Does alkaline phosphatase really predict longevity?

It helps stratify risk, but it does not predict lifespan by itself. The Swedish AMORIS study of 1,224 centenarians found that people who reached 100 tended to have lower ALP as part of a broader favorable biomarker pattern, while the NHANES study of 34,000 adults linked the highest ALP quartile with higher all-cause mortality. Use ALP as one piece of the cardiometabolic and liver-bone picture.

---

Key Takeaways

• ALP is a multi-organ enzyme (liver, bones, intestine) and one of the 9 PhenoAge biomarkers for biological age calculation
• The “normal” range isn’t enough: high-normal values, rising trends, and very low values can all deserve context
• NHANES links higher ALP with higher mortality, but the fully adjusted cardiovascular signal is more modest than raw rates suggest
• Higher ALP can travel with vascular-calcification biology, especially when mineral metabolism, kidney disease, or inflammation are involved
• Centenarians tended to have lower ALP in AMORIS, but exceptional longevity was a multi-marker pattern, not an ALP-only story
• 6 strategies to optimize context: protect the liver, correct vitamin D/bone-mineral problems, exercise regularly, control weight and metabolic syndrome, support gut health, and investigate persistent low ALP
• SuperAge calculates ALP’s impact on your biological age and shows you the trend over time

---

Start Monitoring Your Alkaline Phosphatase Today

Alkaline phosphatase is one of those hidden numbers in your report that can reveal more than a routine liver-bone check. It is associated with cardiovascular and all-cause mortality in large cohorts and is a key component of your calculated biological age.

Next time you get blood tests, don’t just check that ALP is “in the normal range.” Ask yourself: is it rising or falling compared to last year? Is my GGT in the normal range? Do vitamin D, calcium, phosphate, bilirubin, kidney function, and liver enzymes tell the same story?

Want to transform your blood tests into a longevity indicator? Download SuperAge and discover your biological age in seconds.

---

References

1. Li, Y. et al. (2023). “Association between serum alkaline phosphatase and all-cause mortality: NHANES 1999-2014.” Frontiers in Endocrinology. DOI: 10.3389/fendo.2023.1217369
2. Wannamethee, S. G. et al. (2013). “Alkaline phosphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men.” Arteriosclerosis, Thrombosis, and Vascular Biology. DOI: 10.1161/ATVBAHA.112.300826
3. Murata, S. et al. (2023). “Blood biomarker profiles and exceptional longevity: comparison of centenarians and non-centenarians in a 35-year follow-up of the Swedish AMORIS cohort.” GeroScience. DOI: 10.1007/s11357-023-00936-w
4. Sheen, C. R. et al. (2015). “Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification.” Journal of Bone and Mineral Research. DOI: 10.1002/jbmr.2420
5. Webber, M. et al. (2013). “Association between serum alkaline phosphatase and metabolic syndrome.” Journal of Clinical Endocrinology & Metabolism. DOI: 10.1210/jc.2013-1442
6. Kühn, F. et al. (2020). “Intestinal alkaline phosphatase targets the gut barrier to prevent aging.” JCI Insight. DOI: 10.1172/jci.insight.134049
7. Kaliannan, K. et al. (2015). “Intestinal alkaline phosphatase prevents metabolic syndrome in mice.” eBioMedicine (The Lancet). DOI: 10.1016/j.ebiom.2015.11.033
8. Levine, M. E. et al. (2018). “An epigenetic biomarker of aging for lifespan and healthspan.” Aging, 10(4), 573-591. DOI: 10.18632/aging.101414
9. Lee, C.-T. et al. (2025). “Moderate-severe aortic arch calcification and high serum alkaline phosphatase co-modify the risk of cardiovascular events and mortality among chronic hemodialysis patients.” Renal Failure. DOI: 10.1080/0886022X.2024.2449572
10. Maruyama, Y. et al. (2025). “Higher serum alkaline phosphatase is a risk factor of death and new hip fracture: a nationwide Japanese dialysis registry analysis.” Kidney360. DOI: 10.34067/KID.0000000656
11. O’Brien, K. D. et al. (2025). “Therapeutic approaches for the treatment of genetic and acquired cardiovascular calcification.” Frontiers in Cardiovascular Medicine. DOI: 10.3389/fcvm.2025.1636432
12. Boccardi, V. et al. (2021). “Serum alkaline phosphatase is elevated and inversely correlated with cognitive functions in subjective cognitive decline: results from the ReGAl 2.0 project.” Aging Clinical and Experimental Research. DOI: 10.1007/s40520-020-01572-6
13. Yang, Q. et al. (2024). “Nonlinear association of serum liver enzymes with cognitive performance in older adults: a population-based analysis of NHANES.” PLOS One. DOI: 10.1371/journal.pone.0306839
14. Kwo, P. Y. et al. (2017). “ACG Clinical Guideline: Evaluation of abnormal liver chemistries.” American Journal of Gastroenterology. DOI: 10.1038/ajg.2016.517
15. Newcastle Hospitals Laboratories. (2024). “Guidance for the investigation of low alkaline phosphatase (ALP) in adults.” PDF

---

Last updated: July 7, 2026. This article is regularly reviewed for accuracy. The information provided does not replace professional medical advice.